Rising interest in ADC linker and antibody conjugation technology for the development of homogenous antibody drug conjugates (ADCs) is driven by the need for targeted cancer therapies with improved safety and efficacy profiles. Since the voluntary withdrawal of the first FDA-approved ADC, Mylotarg, in 2000 due to safety concerns and poor clinical benefits, researchers have made significant progress in identifying key factors for successful ADCs. These include optimizing the structure and design of ADCs, minimizing systemic toxicity, validating tumor biomarkers, selecting the appropriate antibody, and ensuring the potency of the payload.

To address the challenges associated with conventional ADCs, advanced ADC linker and conjugation technologies have been developed. These technologies aim to produce ADCs with improved stability, toxicity profiles, and controlled release of the cytotoxic payload at the desired location. A key characteristic of these advanced technologies is the ability to generate controlled, homogenous ADCs that are site-selective, enabling them to be utilized as targeted anti-cancer therapies.

We foresee that the growing demand for targeted, stable, and non-toxic ADCs will continue to drive the adoption and market growth of ADC linker technology and antibody conjugation technologies. As more homogenous ADCs are developed using these advanced technologies, we expect to see improvements in the clinical outcomes of cancer patients treated with these targeted therapies.

We Sinoway could supply you high purity ADC linkers, such as Amino-PEG4-Alcohol (CAS No.: 86770-74-3), SMCC (CAS No.: 64987-85-5), VAL-CIT-PAB(CAS No.: 159857-79-1), etc. We also can supply you one-stop CDMO service according to your requirements. Please feel free to contact us at xie@china-sinoway.com